Belantamab Mafodotin
Belantamab mafodotin is an antibody-drug conjugate used to treat relapsed or refractory multiple myeloma in patients who have received prior therapies. It works by targeting BCMA proteins on cancer cells and delivering a cytotoxic agent directly to them. This treatment is typically reserved for patients who have progressed after other standard therapies.
Belantamab mafodotin is a targeted cancer therapy that delivers chemotherapy directly to multiple myeloma cells via an antibody that recognizes BCMA.
This medication carries a boxed (black box) warning — the strongest type of FDA warning. Review the full prescribing information before use.
Key facts at a glance
- ATC
- L01FX15
- RxNorm
- 2387834
- Generic
- Belantamab Mafodotin
- Class
- atc-l01
- Brands
- Blenrep
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- injection
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 500mg twice daily
- Maximum
- consult physician
- Frequency
- every 12 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 250mg twice daily
- Maximum
- consult physician
- Frequency
- every 12 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 400mg daily
- Maximum
- consult physician
- Frequency
- once daily
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
8 groupspregnancy
all trimestersavoid
Avoid use during pregnancy. Women of childbearing potential should use effective contraception during treatment and for at least 4 months after the last dose.
Regular fetal monitoring recommended if exposure occurs
Use of this medication in this population requires careful consideration of risks and benefits.
lactation
breastfeedingavoid
Breastfeeding should be avoided during treatment and for at least 3 months after the last dose due to potential excretion in breast milk
N/A
Use of this medication in this population requires careful consideration of risks and benefits.
pediatric_age
pediatric allnot applicable
Not indicated for use in pediatric patients. Safety and efficacy in patients under 18 years of age have not been established.
N/A
Use of this medication in this population requires careful consideration of risks and benefits.
geriatric
elderly 65 and olderno_adjustment
No dose adjustment required based on age alone. Monitor for adverse reactions, particularly corneal toxicity and infusion-related reactions.
Regular ophthalmologic exams recommended due to increased risk of corneal changes in elderly
Use with caution and monitor for adverse effects.
renal_impairment
mild to moderateno_adjustment
No dose adjustment recommended for mild to moderate renal impairment. Patients with severe renal impairment were not studied in clinical trials.
Monitor renal function regularly; monitor for increased adverse events
Use with caution and monitor for adverse effects.
renal_impairment
severeuse_with_caution
Use with caution in patients with severe renal impairment; benefits should outweigh potential risks. Consider closer monitoring.
Enhanced monitoring of renal function and adverse events recommended
Use with caution and monitor for adverse effects.
hepatic_impairment
mildno_adjustment
No dose adjustment recommended for mild hepatic impairment (bilirubin ≤ULN and AST >ULN, or bilirubin >1 to 1.5x ULN)
Monitor liver function tests regularly
Use with caution and monitor for adverse effects.
hepatic_impairment
moderate to severeuse_with_caution
Use with caution in patients with moderate to severe hepatic impairment. Benefits should outweigh potential risks.
Enhanced monitoring of liver function tests recommended
Use with caution and monitor for adverse effects.
Statistics and clinical data
Drug class
BCMA-directed antibody-drug conjugate for multiple myeloma treatment
FDA approval year
Initial FDA approval date for Belantamab mafodotin
Indication
Therapeutic indication for adult patients who have received at least 4 prior therapies
Target
Molecular target of the monoclonal antibody component
Belantamab mafodotin-blmf is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
Belantamab mafodotin is an antibody-drug conjugate consisting of an afucosylated IgG1 antibody that specifically binds to BCMA (B-cell maturation antigen) expressed on multiple myeloma cells. Upon binding, the drug is internalized and releases the mcMMAF component, a microtubule inhibitor that disrupts cell division and causes cell death.
Common side effects include keratopathy (eye toxicity), thrombocytopenia, anemia, infusion-related reactions, and blurred vision. Regular ophthalmologic examinations are required during treatment. The drug may cause fetal harm and should not be used during pregnancy. It is administered intravenously by healthcare professionals.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy